Leo Pharma eczema drug makes Express Scripts preferred product list
Express Scripts, the biggest pharmacy benefit manager (PBM) in the US, has made Leo Pharma’s Adbry one of its preferred products, putting the Danish atopic eczema treatment at the same level as its blockbuster competition, Sanofi’s Dupixent.
by ulrich quistgaard, translated by daniel pedersen
Leo Pharma’s atopic eczema drug, Adbry (tralokinumab), is now on the list of preferred drugs at Express Scripts, which is the biggest pharmacy benefit manager (PBM) in the US with 22 million customers across 50 states.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
England and Wales reject Leo Pharma's eczema drug
For subscribers
.jpg&w=384&q=75)
